



 Age/Gender
 : 38 Y 0 M 22 D/F

 UHID/MR No
 : CINR.0000158816

 Visit ID
 : CINROPV210332

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 9630813500 Collected : 11/Nov/2023 09:58AM Received : 11/Nov/2023 01:02PM

Reported : 11/Nov/2023 03:54PM

Status : Final Report
Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY	/ HEALTH ANNUAL	DI IIS CHECK -	FEMALE - 2D ECHO - E	AN INDIA - EV2324
AROOI LIVII - WILDIWITELL - 1 OLL BOD	I IILALIII ANNOAL	LOS CITECIO	I LIMALL - 2D LOTTO - F	AN INDIA - 1 12324
Test Name	Result	Unit	Pio Pof Pango	Method
i est Naille	Result	Onit	Bio. Ref. Range	Wethou

HAEMOGLOBIN	13	g/dL	12-15	Spectrophotometer
PCV	38.20	%	36-46	Electronic pulse & Calculation
RBC COUNT	4.14	Million/cu.mm	3.8-4.8	Electrical Impedence
MCV	92.5	fL	83-101	Calculated
MCH	31.4	pg	27-32	Calculated
MCHC	34	g/dL	31.5-34.5	Calculated
R.D.W	15.1	%	11.6-14	Calculated
TOTAL LEUCOCYTE COUNT (TLC)	8,960	cells/cu.mm	4000-10000	Electrical Impedance
DIFFERENTIAL LEUCOCYTIC COUNT (D	DLC)			
NEUTROPHILS	56.9	%	40-80	Electrical Impedance
LYMPHOCYTES	31.3	%	20-40	Electrical Impedance
EOSINOPHILS	4.1	%	1-6	Electrical Impedance
MONOCYTES	7.4	%	2-10	Electrical Impedance
BASOPHILS	0.3	%	<1-2	Electrical Impedance
ABSOLUTE LEUCOCYTE COUNT				
NEUTROPHILS	5098.24	Cells/cu.mm	2000-7000	Calculated
LYMPHOCYTES	2804.48	Cells/cu.mm	1000-3000	Calculated
EOSINOPHILS	367.36	Cells/cu.mm	20-500	Calculated
MONOCYTES	663.04	Cells/cu.mm	200-1000	Calculated
BASOPHILS	26.88	Cells/cu.mm	0-100	Calculated
PLATELET COUNT	193000	cells/cu.mm	150000-410000	Electrical impedence
ERYTHROCYTE SEDIMENTATION RATE (ESR)	20	mm at the end	0-20	Modified Westegren method

RBCs: are normocytic normochromic

WBCs: are normal in total number with normal distribution and morphology.

PLATELETS: appear adequate in number.

HEMOPARASITES: negative

Page 1 of 17







: Mrs.MOHAN KALA SHARMA

Age/Gender

: 38 Y 0 M 22 D/F

UHID/MR No Visit ID : CINR.0000158816

Ref Doctor

: CINROPV210332 : Dr.SELF

Emp/Auth/TPA ID : 9630813500

Collected

: 11/Nov/2023 09:58AM

Received

: 11/Nov/2023 01:02PM : 11/Nov/2023 03:54PM

Reported Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

Test Name Result Unit Bio. Ref. Range Method

IMPRESSION: NORMOCYTIC NORMOCHROMIC BLOOD PICTURE

Page 2 of 17



SIN No:BED230277358

NABL renewal accreditation under process

THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED- RRL BANGALORE







Age/Gender : 38 Y 0 M 22 D/F UHID/MR No : CINR.0000158816

Visit ID : CINROPV210332

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 9630813500 Collected : 11/Nov/2023 09:58AM

Received : 11/Nov/2023 01:02PM Reported : 11/Nov/2023 05:00PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY	HEALTH ANNUAL	PLUS CHECK -	FEMALE - 2D ECHO - F	PAN INDIA - FY2324
Test Name	Result	Unit	Bio. Ref. Range	Method

BLOOD GROUP ABO AND RH FACTOR, WHOLE BLOOD EDTA					
BLOOD GROUP TYPE	0	Microplate Hemagglutination			
Rh TYPE	Positive	Microplate Hemagglutination			

Page 3 of 17

SIN No:BED230277358

NABL renewal accreditation under process

THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED- RRL BANGALORE







: Mrs.MOHAN KALA SHARMA

Age/Gender

: 38 Y 0 M 22 D/F

UHID/MR No

: CINR.0000158816

Visit ID

: CINROPV210332

Ref Doctor Emp/Auth/TPA ID : Dr.SELF

: 9630813500

Collected

: 11/Nov/2023 12:33PM

Received

: 11/Nov/2023 03:07PM

Reported

Status

: 11/Nov/2023 03:44PM

Sponsor Name

: Final Report

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY	HEALTH ANNUAL	PLUS CHECK -	FEMALE - 2D ECHO - F	AN INDIA - FY2324
Test Name	Result	Unit	Bio. Ref. Range	Method

GLUCOSE, FASTING , NAF PLASMA	93	mg/dL	70-100	HEXOKINASE
-------------------------------	----	-------	--------	------------

Comment:

As per American Diabetes Guidelines, 2023

Fasting Glucose Values in mg/dL	Interpretation
70-100 mg/dL	Normal
100-125 mg/dL	Prediabetes
≥126 mg/dL	Diabetes
<70 mg/dL	Hypoglycemia

Note:

- 1. The diagnosis of Diabetes requires a fasting plasma glucose of > or = 126 mg/dL and/or a random / 2 hr post glucose value of > or = 200 mg/dL on at least 2
- 2. Very high glucose levels (>450 mg/dL in adults) may result in Diabetic Ketoacidosis & is considered critical.

GLUCOSE, POST PRANDIAL (PP), 2	104	mg/dL	70-140	HEXOKINASE
HOURS, SODIUM FLUORIDE PLASMA (2				
HR)				

Comment:

It is recommended that FBS and PPBS should be interpreted with respect to their Biological reference ranges and not with each

Conditions which may lead to lower postprandial glucose levels as compared to fasting glucose levels may be due to reactive hypoglycemia, dietary meal content, duration or timing of sampling after food digestion and absorption, medications such as insulin preparations, sulfonylureas, amylin analogues, or conditions such as overproduction of insulin.

Page 4 of 17

SIN No:PLF02053678,PLP1386492 NABL renewal accreditation under process

THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED- RRL BANGALORE





 Age/Gender
 : 38 Y 0 M 22 D/F

 UHID/MR No
 : CINR.0000158816

 Visit ID
 : CINROPV210332

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 9630813500 Collected : 11/Nov/2023 09:58AM Received : 11/Nov/2023 12:19PM

Reported : 11/Nov/2023 12:19PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324 Test Name Result Unit Bio. Ref. Range Method

HBA1C, GLYCATED HEMOGLOBIN , WHOLE BLOOD EDTA	5.4	%	HPLC
ESTIMATED AVERAGE GLUCOSE (eAG) , WHOLE BLOOD EDTA	108	mg/dL	Calculated

Comment:

Reference Range as per American Diabetes Association (ADA) 2023 Guidelines:

REFERENCE GROUP	нва1С %
NON DIABETIC	<5.7
PREDIABETES	5.7 – 6.4
DIABETES	≥ 6.5
DIABETICS	
EXCELLENT CONTROL	6 – 7
FAIR TO GOOD CONTROL	7 – 8
UNSATISFACTORY CONTROL	8 – 10
POOR CONTROL	>10

Note: Dietary preparation or fasting is not required.

- 1. HbA1C is recommended by American Diabetes Association for Diagnosing Diabetes and monitoring Glycemic Control by American Diabetes Association guidelines 2023.
- 2. Trends in HbA1C values is a better indicator of Glycemic control than a single test.
- 3. Low HbA1C in Non-Diabetic patients are associated with Anemia (Iron Deficiency/Hemolytic), Liver Disorders, Chronic Kidney Disease. Clinical Correlation is advised in interpretation of low Values.
- 4. Falsely low HbA1c (below 4%) may be observed in patients with clinical conditions that shorten erythrocyte life span or decrease mean erythrocyte age. HbA1c may not accurately reflect glycemic control when clinical conditions that affect erythrocyte survival are present.
- 5. In cases of Interference of Hemoglobin variants in HbA1C, alternative methods (Fructosamine) estimation is recommended for Glycemic Control

A: HbF >25%

- B: Homozygous Hemoglobinopathy.
- (Hb Electrophoresis is recommended method for detection of Hemoglobinopathy)

Page 5 of 17

SIN No:EDT230102361

NABL renewal accreditation under process

THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED- RRL BANGALORE





 Age/Gender
 : 38 Y 0 M 22 D/F

 UHID/MR No
 : CINR.0000158816

 Visit ID
 : CINROPV210332

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 9630813500 Collected : 11/Nov/2023 09:58AM Received : 11/Nov/2023 12:22PM

Reported : 11/Nov/2023 12:22PM : 11/Nov/2023 02:07PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY	HEALTH ANNUAL	PLUS CHECK -	FEMALE - 2D ECHO - F	PAN INDIA - FY2324
Test Name	Result	Unit	Bio. Ref. Range	Method

LIPID PROFILE , SERUM				
TOTAL CHOLESTEROL	175	mg/dL	<200	CHO-POD
TRIGLYCERIDES	116	mg/dL	<150	GPO-POD
HDL CHOLESTEROL	56	mg/dL	40-60	Enzymatic Immunoinhibition
NON-HDL CHOLESTEROL	119	mg/dL	<130	Calculated
LDL CHOLESTEROL	95.7	mg/dL	<100	Calculated
VLDL CHOLESTEROL	23.2	mg/dL	<30	Calculated
CHOL / HDL RATIO	3.12		0-4.97	Calculated

Comment:

Reference Interval as per National Cholesterol Education Program (NCEP) Adult Treatment Panel III Report.

	Desirable	Borderline High	High	Very High
TOTAL CHOLESTEROL	< 200	200 - 239	≥ 240	
TRIGLYCERIDES	<150	150 - 199	200 - 499	≥ 500
III .I DI .	Optimal < 100 Near Optimal 100-129	130 - 159	160 - 189	≥ 190
HDL	≥ 60	*		
INON-HDL CHOLESTEROL	Optimal <130; Above Optimal 130-159	160-189	190-219	>220

- 1. Measurements in the same patient on different days can show physiological and analytical variations.
- 2. NCEP ATP III identifies non-HDL cholesterol as a secondary target of therapy in persons with high triglycerides.
- 3. Primary prevention algorithm now includes absolute risk estimation and lower LDL Cholesterol target levels to determine eligibility of drug therapy.
- **4.** Low HDL levels are associated with Coronary Heart Disease due to insufficient HDL being available to participate in reverse cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues.
- **5.** As per NCEP guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is recommended.
- 6. VLDL, LDL Cholesterol Non HDL Cholesterol, CHOL/HDL RATIO, LDL/HDL RATIO are calculated parameters when Triglycerides are below 350mg/dl. When Triglycerides are more than 350 mg/dl LDL cholesterol is a direct measurement.

Page 6 of 17

SIN No:SE04537591

NABL renewal accreditation under process

THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED- RRL BANGALORE







: Mrs.MOHAN KALA SHARMA

Age/Gender

: 38 Y 0 M 22 D/F

UHID/MR No

: CINR.0000158816

Visit ID

: CINROPV210332

Ref Doctor Emp/Auth/TPA ID : Dr.SELF : 9630813500 Collected

: 11/Nov/2023 09:58AM

Received

: 11/Nov/2023 12:22PM

Reported

Status

: 11/Nov/2023 02:07PM

Sponsor Name

: Final Report

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY	HEALTH ANNUAL	PLUS CHECK -	FEMALE - 2D ECHO - F	PAN INDIA - FY2324
Test Name	Result	Unit	Bio. Ref. Range	Method

LIVER FUNCTION TEST (LFT) , SERUM				
BILIRUBIN, TOTAL	1.77	mg/dL	0.3-1.2	DPD
BILIRUBIN CONJUGATED (DIRECT)	0.30	mg/dL	<0.2	DPD
BILIRUBIN (INDIRECT)	1.47	mg/dL	0.0-1.1	Dual Wavelength
ALANINE AMINOTRANSFERASE (ALT/SGPT)	18	U/L	<35	IFCC
ASPARTATE AMINOTRANSFERASE (AST/SGOT)	20.0	U/L	<35	IFCC
ALKALINE PHOSPHATASE	95.00	U/L	30-120	IFCC
PROTEIN, TOTAL	7.37	g/dL	6.6-8.3	Biuret
ALBUMIN	4.22	g/dL	3.5-5.2	BROMO CRESOL GREEN
GLOBULIN	3.15	g/dL	2.0-3.5	Calculated
A/G RATIO	1.34		0.9-2.0	Calculated

Comment:

LFT results reflect different aspects of the health of the liver, i.e., hepatocyte integrity (AST & ALT), synthesis and secretion of bile (Bilirubin, ALP), cholestasis (ALP, GGT), protein synthesis (Albumin)

Common patterns seen:

1. Hepatocellular Injury:

- AST Elevated levels can be seen. However, it is not specific to liver and can be raised in cardiac and skeletal injuries.
- ALT Elevated levels indicate hepatocellular damage. It is considered to be most specific lab test for hepatocellular injury. Values also correlate well with increasing BMI.
- Disproportionate increase in AST, ALT compared with ALP.
- Bilirubin may be elevated.
- AST: ALT (ratio) In case of hepatocellular injury AST: ALT > 1In Alcoholic Liver Disease AST: ALT usually >2. This ratio is also seen to be increased in NAFLD, Wilsons's diseases, Cirrhosis, but the increase is usually not >2.

2. Cholestatic Pattern:

- ALP Disproportionate increase in ALP compared with AST, ALT.
- Bilirubin may be elevated.
- ALP elevation also seen in pregnancy, impacted by age and sex.
- To establish the hepatic origin correlation with GGT helps. If GGT elevated indicates hepatic cause of increased ALP.

3. Synthetic function impairment:

- Albumin- Liver disease reduces albumin levels.
- Correlation with PT (Prothrombin Time) helps.

Page 7 of 17





: Mrs.MOHAN KALA SHARMA

Age/Gender

: 38 Y 0 M 22 D/F

UHID/MR No Visit ID

: CINR.0000158816

Ref Doctor

: Dr.SELF Emp/Auth/TPA ID

: CINROPV210332

: 9630813500

Collected

: 11/Nov/2023 09:58AM

Received

: 11/Nov/2023 12:22PM : 11/Nov/2023 02:07PM

Reported Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

Test Name Result Unit

Bio. Ref. Range

Method

Page 8 of 17



SIN No:SE04537591

NABL renewal accreditation under process

THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED- RRL BANGALORE

Apollo Health and Lifestyle Limited (CIN-U85110TG2000PLC115819)

Regd. Office: 1-10-60/62, Ashoka Raghupathi Chambers, 5th Floor, Begumpet, Hyderabad, Telang www.apollohl.com | Email ID: enquiry@apollohl.com, Ph No: 040-4904 7777, Fax No: 4904 7744 na - 500 016 | APOLLO CLINICS NETWORK







Age/Gender : 38 Y 0 M 22 D/F UHID/MR No : CINR.0000158816

Visit ID : CINROPV210332

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 9630813500 Collected : 11/Nov/2023 09:58AM Received : 11/Nov/2023 12:22PM

Received : 11/Nov/2023 12:22PM Reported : 11/Nov/2023 02:07PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY	HEALTH ANNUAL	PLUS CHECK -	FEMALE - 2D ECHO - F	PAN INDIA - FY2324
Test Name	Result	Unit	Bio. Ref. Range	Method

RENAL PROFILE/KIDNEY FUNCTION TEST (RFT/KFT) , SERUM					
CREATININE	0.61	mg/dL	0.72 – 1.18	JAFFE METHOD	
UREA	28.40	mg/dL	17-43	GLDH, Kinetic Assay	
BLOOD UREA NITROGEN	13.3	mg/dL	8.0 - 23.0	Calculated	
URIC ACID	5.63	mg/dL	2.6-6.0	Uricase PAP	
CALCIUM	9.40	mg/dL	8.8-10.6	Arsenazo III	
PHOSPHORUS, INORGANIC	3.74	mg/dL	2.5-4.5	Phosphomolybdate Complex	
SODIUM	136	mmol/L	136–146	ISE (Indirect)	
POTASSIUM	4.4	mmol/L	3.5–5.1	ISE (Indirect)	
CHLORIDE	104	mmol/L	101–109	ISE (Indirect)	

Page 9 of 17



SIN No:SE04537591

NABL renewal accreditation under process

THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED- RRL BANGALORE







: Mrs.MOHAN KALA SHARMA

Age/Gender

: 38 Y 0 M 22 D/F

UHID/MR No Visit ID : CINR.0000158816 : CINROPV210332

Ref Doctor

: Dr.SELF

Emp/Auth/TPA ID : 9630813500

Collected

: 11/Nov/2023 09:58AM

Received

: 11/Nov/2023 12:22PM : 11/Nov/2023 02:07PM

Reported Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

Test Name	Result	Unit	Bio. Ref. Range	Method
-----------	--------	------	-----------------	--------

GAMMA GLUTAMYL TRANSPEPTIDASE	19.00	U/L	<38	IFCC	
(GGT) . SERUM					

Page 10 of 17

SIN No:SE04537591

NABL renewal accreditation under process

THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED- RRL BANGALORE







 Age/Gender
 : 38 Y 0 M 22 D/F

 UHID/MR No
 : CINR.0000158816

 Visit ID
 : CINROPV210332

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 9630813500 Collected : 11/Nov/2023 09:58AM

Received : 11/Nov/2023 12:21PM Reported : 11/Nov/2023 01:24PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF IMMUNOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY	HEALTH ANNUAL	PLUS CHECK -	FEMALE - 2D ECHO - F	PAN INDIA - FY2324
Test Name	Result	Unit	Bio. Ref. Range	Method

THYROID PROFILE TOTAL (T3, T4, TSH), SERUM						
TRI-IODOTHYRONINE (T3, TOTAL)	0.82	ng/mL	0.7-2.04	CLIA		
THYROXINE (T4, TOTAL)	7.93	μg/dL	5.48-14.28	CLIA		
THYROID STIMULATING HORMONE (TSH)	3.563	μIU/mL	0.34-5.60	CLIA		

Comment:

For pregnant females	Bio Ref Range for TSH in uIU/ml (As per American Thyroid Association)
First trimester	0.1 - 2.5
Second trimester	0.2 - 3.0
Third trimester	0.3 - 3.0

- **1.** TSH is a glycoprotein hormone secreted by the anterior pituitary. TSH activates production of T3 (Triiodothyronine) and its prohormone T4 (Thyroxine). Increased blood level of T3 and T4 inhibit production of TSH.
- 2. TSH is elevated in primary hypothyroidism and will be low in primary hyperthyroidism. Elevated or low TSH in the context of normal free thyroxine is often referred to as sub-clinical hypo- or hyperthyroidism respectively.
- 3. Both T4 & T3 provides limited clinical information as both are highly bound to proteins in circulation and reflects mostly inactive hormone. Only a very small fraction of circulating hormone is free and biologically active.
- 4. Significant variations in TSH can occur with circadian rhythm, hormonal status, stress, sleep deprivation, medication & circulating antibodies.

TSH	Т3	Т4	FT4	Conditions
High	Low	Low	Low	Primary Hypothyroidism, Post Thyroidectomy, Chronic Autoimmune Thyroiditis
High	N	N	N	Subclinical Hypothyroidism, Autoimmune Thyroiditis, Insufficient Hormone Replacement Therapy.
N/Low	Low	Low	Low	Secondary and Tertiary Hypothyroidism
Low	High	High	High	Primary Hyperthyroidism, Goitre, Thyroiditis, Drug effects, Early Pregnancy
Low	N	N	N	Subclinical Hyperthyroidism
Low	Low	Low	Low	Central Hypothyroidism, Treatment with Hyperthyroidism
Low	N	High	High	Thyroiditis, Interfering Antibodies
N/Low	High	N	N	T3 Thyrotoxicosis, Non thyroidal causes
High	High	High	High	Pituitary Adenoma; TSHoma/Thyrotropinoma

Page 11 of 17

SIN No:SPL23159228

NABL renewal accreditation under process

THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED- RRL BANGALORE

Apollo Health and Lifestyle Limited (CIN-U85110TG2000PLC115819)







 Age/Gender
 : 38 Y 0 M 22 D/F

 UHID/MR No
 : CINR.0000158816

 Visit ID
 : CINROPV210332

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 9630813500 Collected : 11/Nov/2023 09:58AM Received : 11/Nov/2023 01:30PM

Reported : 11/Nov/2023 02:02PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF CLINICAL PATHOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY	HEALTH ANNUAL	PLUS CHECK -	FEMALE - 2D ECHO - F	PAN INDIA - FY2324
Test Name	Result	Unit	Bio. Ref. Range	Method

COMPLETE URINE EXAMINATION (CL	JE) , URINE			
PHYSICAL EXAMINATION				
COLOUR	PALE YELLOW		PALE YELLOW	Visual
TRANSPARENCY	CLEAR		CLEAR	Visual
рН	6.0		5-7.5	DOUBLE INDICATOR
SP. GRAVITY	1.025		1.002-1.030	Bromothymol Blue
BIOCHEMICAL EXAMINATION				
URINE PROTEIN	NEGATIVE		NEGATIVE	PROTEIN ERROR OF INDICATOR
GLUCOSE	NEGATIVE		NEGATIVE	GLUCOSE OXIDASE
URINE BILIRUBIN	NEGATIVE		NEGATIVE	AZO COUPLING REACTION
URINE KETONES (RANDOM)	NEGATIVE		NEGATIVE	SODIUM NITRO PRUSSIDE
UROBILINOGEN	NORMAL		NORMAL	MODIFED EHRLICH REACTION
BLOOD	NEGATIVE		NEGATIVE	Peroxidase
NITRITE	NEGATIVE		NEGATIVE	Diazotization
LEUCOCYTE ESTERASE	NEGATIVE		NEGATIVE	LEUCOCYTE ESTERASE
CENTRIFUGED SEDIMENT WET MO	UNT AND MICROSCOPY	•		
PUS CELLS	1-2	/hpf	0-5	Microscopy
EPITHELIAL CELLS	2-3	/hpf	<10	MICROSCOPY
RBC	NIL	/hpf	0-2	MICROSCOPY
CASTS	NIL		0-2 Hyaline Cast	MICROSCOPY
CRYSTALS	ABSENT		ABSENT	MICROSCOPY

Page 12 of 17

SIN No:UR2218358

NABL renewal accreditation under process

THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED- RRL BANGALORE

Apollo Health and Lifestyle Limited (CIN-U85110TG2000PLC115819)

Regd. Office: 1-10-60/62, Ashoka Raghupathi Chambers, 5th Floor, Begumpet, Hyderabad, Telangana - 500 016 | www.apollohl.com | Email ID: enquiry@apollohl.com, Ph No: 040-4904 7777, Fax No: 4904 7744

APOLLO CLINICS NETWORK







: Mrs.MOHAN KALA SHARMA

Age/Gender

: 38 Y 0 M 22 D/F

UHID/MR No Visit ID : CINR.0000158816

Ref Doctor

: CINROPV210332 : Dr.SELF

Emp/Auth/TPA ID : 9630813500

Collected

: 11/Nov/2023 09:58AM

Received

: 11/Nov/2023 01:30PM

Reported Status : 11/Nov/2023 01:51PM : Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT	OF	CLINIC	:AL	PATHOL	OGY
------------	----	--------	-----	--------	-----

Test Name	Result	Unit	Bio. Ref. Range	Method
-----------	--------	------	-----------------	--------

URINE GLUCOSE(POST PRANDIAL)	NEGATIVE	NEGATIVE Dips	stick
------------------------------	----------	---------------	-------

URINE GLUCOSE(FASTING)	NEGATIVE	NEGATIVE	Dipstick
------------------------	----------	----------	----------

Page 13 of 17

SIN No:UPP015757,UF009766 NABL renewal accreditation under process

THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED- RRL BANGALORE











: Mrs.MOHAN KALA SHARMA

Age/Gender

: 38 Y 0 M 22 D/F

UHID/MR No

: CINR.0000158816

Visit ID

: CINROPV210332

Ref Doctor

: Dr.SELF

Emp/Auth/TPA ID : 9630813500

Collected

: 11/Nov/2023 03:10PM

Received

: 12/Nov/2023 06:00PM

Reported

: 14/Nov/2023 01:22PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF CYTOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

	CYTOLOGY NO.	19045/23
I	SPECIMEN	
a	SPECIMEN ADEQUACY	ADEQUATE
b	SPECIMEN TYPE	LIQUID-BASED PREPARATION (LBC)
	SPECIMEN NATURE/SOURCE	CERVICAL SMEAR
c	ENDOCERVICAL-TRANSFORMATION ZONE	ABSENT
d	COMMENTS	SATISFACTORY FOR EVALUATION
II	MICROSCOPY	Superficial and intermediate squamous epithelial cells with benign morphology.
		Negative for intraepithelial lesion/malignancy.
Ш	RESULT	
a	EPITHEIAL CELL	
	SQUAMOUS CELL ABNORMALITIES	NOT SEEN
	GLANDULAR CELL ABNORMALITIES	NOT SEEN
b	ORGANISM	NIL
IV	INTERPRETATION	NEGATIVE FOR INTRAEPITHELIAL LESION OR MALIGNANCY

Pap Test is a screening test for cervical cancer with inherent false negative results. Regular screening and follow-up is recommended (Bethesda-TBS-2014) revised

*** End Of Report ***

Result/s to Follow: PERIPHERAL SMEAR

Page 14 of 17













: Mrs.MOHAN KALA SHARMA

Age/Gender

: 38 Y 0 M 22 D/F

UHID/MR No Visit ID

: CINR.0000158816

: CINROPV210332

Ref Doctor Emp/Auth/TPA ID : Dr.SELF

: 9630813500

Collected

: 11/Nov/2023 03:10PM

Received

: 12/Nov/2023 06:00PM

Reported

: 14/Nov/2023 01:22PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF CYTOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

DR.SHIVARAJA SHETTY M.B.B.S, M.D(Biochemistry) CONSULTANT BIOCHEMIST

Dr. Reshma Stanly M.B.B.S, DNB (Pathology) Consultant Pathologist

Dr.Shobha Emmanuel M.B.B.S,M.D(Pathology) Consultant Pathologist

Dr. Chinki Anupam M.B.B.S, M.D (Pathology) Consultant Pathologist

Page 15 of 17



SIN No:CS070117

This test has been performed at Apollo Health & Lifestyle Ltd, Global Reference Laboratory, Hyderabad

THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED- RRL BANGALORE







: Mrs.MOHAN KALA SHARMA

Age/Gender

: 38 Y 0 M 26 D/F

UHID/MR No Visit ID : CINR.0000158816 : CINROPV210520

Ref Doctor

· Dr SFLF

Collected

: 15/Nov/2023 10:51AM

Received Reported : 15/Nov/2023 01:04PM : 15/Nov/2023 02:28PM

Status

: Final Report

		^_			
DEPA	RTMEN	11 ()F	IMMU	NOL	()(iY

HUL VITAMIN D FY 24 PROMO

Test Name	Result	Unit	Bio. Ref. Range	Method

<mark>VITAMIN D (25 - OH VITAMIN D)</mark> , SERUN	8.04	ng/mL	30 -100	CLIA
--	------	-------	---------	------

Comment:

BIOLOGICAL REFERENCE RANGES

VITAMIN D STATUS	VITAMIN D 25 HYDROXY (ng/mL)
DEFICIENCY	<10
INSUFFICIENCY	10 - 30
SUFFICIENCY	30 - 100
TOXICITY	>100

The biological function of Vitamin D is to maintain normal levels of calcium and phosphorus absorption. 25-Hydroxy vitamin D is the storage form of vitamin D. Vitamin D assists in maintaining bone health by facilitating calcium absorption. Vitamin D deficiency can also cause osteomalacia, which frequently affects elderly patients.

Vitamin D Total levels are composed of two components namely 25-Hydroxy Vitamin D2 and 25-Hydroxy Vitamin D3 both of which are converted into active forms. Vitamin D2 level corresponds with the exogenous dietary intake of Vitamin D rich foods as well as supplements. Vitamin D3 level corresponds with endogenous production as well as exogenous diet and supplements.

Vitamin D from sunshine on the skin or from dietary intake is converted predominantly by the liver into 25-hydroxy vitamin D, which has a long half-life and is stored in the adipose tissue. The metabolically active form of vitamin D, 1,25-di-hydroxy vitamin D, which has a short life, is then synthesized in the kidney as needed from circulating 25-hydroxy vitamin D. The reference interval of greater than 30 ng/mL is a target value established by the Endocrine Society.

Decreased Levels:

Inadequate exposure to sunlight.

Dietary deficiency.

Vitamin D malabsorption.

Severe Hepatocellular disease.

Drugs like Anticonvulsants.

Nephrotic syndrome.

Increased levels:

Vitamin D intoxication.

*** End Of Report ***

Page 16 of 17

THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED- RRL BANGALORE







: Mrs.MOHAN KALA SHARMA

Age/Gender

: 38 Y 0 M 26 D/F

UHID/MR No Visit ID : CINR.0000158816 : CINROPV210520

Ref Doctor

: Dr.SELF

Collected

: 15/Nov/2023 10:51AM

Received Reported : 15/Nov/2023 01:04PM : 15/Nov/2023 02:28PM

Status

: Final Report

	DEPARTMENT OF	IMMUNOLOGY	1	
	HUL VITAMIN D	FY 24 PROMO		
Test Name	Result	Unit	Bio. Ref. Range	Method

DR.SHIVARAJA SHETTY
M.B.B.S,M.D(Biochemistry)
CONSULTANT BIOCHEMIST

Page 17 of 17



SIN No:SPL23160138

 $NABL\ renewal\ accreditation\ under\ process$

THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED- RRL BANGALORE





1099

Name : Mrs. Mohan Kala Sharma

Address: Bangalore

Plan

Age: 38 Y

Sex: F

UHID:CINR.0000158816 OP Number: CINROPV210332

Bill No :CINR-OCR-90602

: ARCOFEMI MEDIWHEEL FEMALE AHC CREDIT PAN INDIA OP AGREEMENT	

Serive Type/ServiceName Date : 11.11.2023 09:41 Sno ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324 LURINE GLUCOSE(FASTING) -2 GAMMA GLUTAMYL TRANFERASE (GGT) A HbA1c, GLYCATED HEMOGLOBIN 42 DECHO 5 LIVER FUNCTION TEST (LFF) 6X-RAY CHEST PA +10 7 GLUCOSE, FASTING 8 HEMOGRAM + PERIPHERAL SMEAR 9 ENT CONSULTATION 10 FITNESS BY GENERAL PHYSICIAN 11 GYNAECOLOGY CONSULTATION 12 DIET CONSULTATION 13 COMPLETE URINE EXAMINATION 14 URINE GLUCOSE(POST PRANDIAL) 15 PERIPHERAL SMEAR -16/ECG 17 BLOOD GROUP ABO AND RH FACTOR 18 LIPID PROFILE 19 BODY MASS INDEX (BMI) 20 LBC PAP TEST- PAPSURE 22+ OPTHAL BY GENERAL PHYSICIAN 22 RENAL PROFILE/RENAL FUNCTION TEST (RFT/KFT) 23 ULTRASOUND - WHOLE ABDOMEN ~ 9 24 THYROID PROFILE (TOTAL T3, TOTAL T4, TSH) 25 DENTAL CONSULTATION -/ 26 GLUCOSE, POST PRANDIAL (PP), 2 HOURS (POST MEAL) 12:00 m

28. Breant decening-15

20. Dero physiotherapy -14

31 Wellness-0



Date

11-11-2023

Department

: GENERAL

MR NO

CINR.0000158816

Doctor

Name

: Mrs. Mohan Kala Sharma

Registration No

Qualification

Age/ Gender

38 Y / Female

Consultation Timing: 09.40			
(D) Dersy	Weight: 63 Kgn	BMI: 269	
Temp: 98. F	Pulse:		Waist Circum: ろうつっつ
	182/18	Resp: 85pm	B.P: 100 Mass

General Examination / Allergies History

Nov ilpors

Clinical Diagnosis & Management Plan

38ym Priz (LSCS) Rfycher comp-6 hiday

PA-SOT NHD Mschally LBC papane. Ly

Follow up date:

Doctor Signature

OPTHAL PRESCRIPTION

PATIENT NAME: mDS. mohan kala Sharma, DATE: White 3

UHID NO: 158216,

AGE:38

OPTOMETRIST NAME: Ms.Swathi

GENDER: F

This is to certify that I have examined

years and findings of his/her eye examination are as follows,

	RIGHT EYE			LEFT EYE				
	SPH	CYL	AXIS	BCVA	SPH	CYL	AXIS	BCVA
Distance		-P/C	1.17		 	0/0	/ / -	DCVA
Add	,	7.00				PICC	no	

PD-RE: 32 LE: 32.

Colour Vision: - s normal (Bb).

Remarks:

Apollo clinic Indiranagar





NAME: MRS MOHAN KALA S	AGE/SEX:	
Ref By: SELF		OP NUMBER: 158
	DATE: 11-11-2023	
M mode and de	······································	

M mode and doppler measurements:

CM	CM	A CONTRACTOR OF THE CONTRACTOR	
AO:2.2		M/sec	Control of the Contro
	IVS(D): 1.2	MV: E Vel: 0.9	A Vel : 0.5
A: 2.4			A vei : 0.5
	LVIDD(D): 3.4	AV Peak: 0.8	
	LVPW(D): 1.2	PV Peak: 0.5	
	IVS(S): 1.3	1 V Feak: 0.5	A CONTRACTOR OF THE PROPERTY O
		Constitution of the consti	
	LVID(S): 2.5		
The galaxy countries of the galaxy and the galaxy of the g	LVPW(S): 1.3		
	LVEF: 55%		
	TAPSE: 2.2		
scriptive findings:	and a second		

and the state of t
Normal
Normal
The second secon
Normal
Normal
Motugi
Normal
Normal
The second secon
Normal
Normal
Normal
Normal





HOSPITALS Pericardium:	APOITO Expertise. Closer	NGRESTERS
	Normal Lyberuse. Closer	
IVC:		
	Normal	
Others		
		-
		-

IMPRESSION:

Normal cardiac chambers

No Regional wall motion abnormality

No MR/AR/TR


No clot/vegetation/pericardial effusion


Normal LV systolic function - LVEF= 55%


DR JAGADEESH H V MD,DM


CONSULTANT CARDIOLOGIST

Dr. JAGADEESH H V MBBS,MD, DM(Cardio)
Consultant Cardiologist
KMC Reg No.86848
Apollo Clinic









From: Customer Care :Mediwheel : New Delhi <customercare@mediwheel.in>

Sent: 03 November 2023 11:56

To: Corporate Apollo Clinic <corporate@apolloclinic.com>

Cc: Wellness: Mediwheel: New Delhi <wellness@mediwheel.in>; Network: Mediwheel: New Delhi

<network@mediwheel.in>; deepak <deepak.c@apolloclinic.com>

Subject: Health Checkup Booking No. 2 Annual

Dear Team,

Please note the following bookings and confirm the same.

S. No.	Company Name	PACKAGE NAME	Broukhnji (fil	EMIEL NVANVIE	1.(3)	GEVEE:	EMAIL
1	Arcofemi/Mediwheel/MALE/FEMALE	Arcofemi MediWheel Full Body Health Annual Plus Check Female 2D ECHO (Metro)	bob\$43194	mohan kala sharma	36	Female	sam0343@gmail.c
2		Arcofemi MediWheel Full Body Annual Plus Male Above 50 2D ECHO (Metro)		Bishnu Prasad Sharma			sam0343@gmail.c

Thanks & Regards





Patient Name : Mrs. Mohan Kala Sharma Age/Gender : 38 Y/F

UHID/MR No.

: CINR.0000158816

OP Visit No

: CINROPV210332

Sample Collected on

: RAD2148421

Reported on Specimen

: 11-11-2023 17:46

Ref Doctor

LRN#

: SELF

Emp/Auth/TPA ID : 9630813500

DEPARTMENT OF RADIOLOGY

X-RAY CHEST PA

Both lung fields and hila are normal.

No obvious active pleuro-parenchymal lesion seen .

Both costophrenic and cardiophrenic angles are clear.

Both diaphragms are normal in position and contour.

Thoracic wall and soft tissues appear normal.

CONCLUSION:

No obvious abnormality seen

Dr. DHANALAKSHMI B MBBS, DMRD

Radiology



Patient Name : Mrs. Mohan Kala Sharma Age/Gender : 38 Y/F

 UHID/MR No.
 : CINR.0000158816
 OP Visit No
 : CINROPV210332

 Sample Collected on
 : 11-11-2023 14:26

 Sample Collected on
 : 11-12

 LRN#
 : RAD2148421
 Specimen
 : 11-12

Ref Doctor : SELF

Emp/Auth/TPA ID : 9630813500

DEPARTMENT OF RADIOLOGY

ULTRASOUND - WHOLE ABDOMEN

LIVER: Appears normal in size, shape and echopattern. No focal parenchymal lesions identified. No evidence of intra/extrahepatic biliary tree dilatation noted. Portal vein appears to be of normal size.

GALLBLADDER: Moderately distended. No definite calculi identified. No evidence of abnormal wall thickening noted.

SPLEEN: Appears normal in size, shape and echopattern. No focal parenchymal lesions identified.

PANCREAS: Obscured by bowel gas. However, the visualized portion appear normal.

KIDNEYS: Both kidneys appear normal in size, shape and echopattern. Corticomedullary differentiation appears maintained. No evidence of calculi or hydronephrosis on either side.

URINARY BLADDER: Distended and appears normal. No evidence of abnormal wall thickening noted.

UTERUS: Retroverted and appears normal in size. Myometrial echoes appear normal. The endometrial lining appears intact. Endometrium measures 7 mm. Copper-T not seen in situ seen i cervix.

OVARIES: Both ovaries appearing normal in size and echopattern.

No free fluid is seen.

IMPRESSION:

NO SIGNIFICANT SONOGRAPHIC ABNORMALITY DETECTED.

Dr. DHANALAKSHMI B

MBBS, DMRD

Radiology



: 11-11-2023 14:26

Patient Name : Mrs. Mohan Kala Sharma Age/Gender : 38 Y/F

UHID/MR No. : CINR.0000158816 **OP Visit No** : CINROPV210332

Ref Doctor : SELF

Emp/Auth/TPA ID : 9630813500

DEPARTMENT OF RADIOLOGY

Reported on

ULTRASOUND - WHOLE ABDOMEN

LIVER: Appears normal in size, shape and echopattern. No focal parenchymal lesions identified. No evidence of intra/extrahepatic biliary tree dilatation noted. Portal vein appears to be of normal size.

GALLBLADDER: Moderately distended. No definite calculi identified. No evidence of abnormal wall thickening noted.

SPLEEN: Appears normal in size, shape and echopattern. No focal parenchymal lesions identified.

PANCREAS: Obscured by bowel gas. However, the visualized portion appear normal.

KIDNEYS: Both kidneys appear normal in size, shape and echopattern. Corticomedullary differentiation appears maintained. No evidence of calculi or hydronephrosis on either side.

URINARY BLADDER: Distended and appears normal. No evidence of abnormal wall thickening noted.

UTERUS: Retroverted and appears normal in size. Myometrial echoes appear normal. The endometrial lining appears intact. Endometrium measures 7 mm. Copper-T not seen in situ seen i cervix.

OVARIES: Both ovaries appearing normal in size and echopattern.

No free fluid is seen.

Sample Collected on

IMPRESSION:

 $NO\ SIGNIFICANT\ SONOGRAPHIC\ ABNORMALITY\ DETECTED.$

Dr. DHANALAKSHMI B

MBBS, DMRD

Radiology